The collaboration combines Myriad’s US laboratory capabilities with SOPHiA’s decentralized network of more than 800 institutions across 70-plus countries.
Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop and provide pharmaceutical companies with a global liquid biopsy companion diagnostic test, leveraging each company’s distinct market strengths.
The partnership will combine Myriad’s advanced laboratory capabilities in the US to support global testing for clinical trials with SOPHiA GENETICS’ decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.
“Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics,” says Sam Raha, president and CEO of Myriad Genetics, in a release. “We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu, and support the growth of our CDx programs.”
Focus on MSK-ACCESS Platform
The companies will initially focus on the liquid biopsy application MSK-ACCESS powered with SOPHiA DDM. Developed in collaboration with Memorial Sloan Kettering Cancer Center, the test detects actionable genomic alterations from a single blood draw using proprietary algorithms that analyze circulating tumor DNA.
By developing the application into a companion diagnostic, the companies aim to expand patient access to the tumor profiling test and advance personalized healthcare delivery.
Under the collaboration structure, Myriad will pursue regulatory submissions in the US while SOPHiA GENETICS will manage regulatory submissions outside the US. Both companies will collaborate across development activities.
“This collaboration represents a pivotal moment for the industry,” says Jurgi Camblong, co-founder and CEO of SOPHiA GENETICS, in a release. “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics.”
SOPHiA GENETICS and Myriad will participate in a panel discussion at the World CB and CDx Summit in Boston to provide additional details on the collaboration.
ID 92236248 © Anyaivanova | Dreamstime.com
